TY - JOUR
T1 - The Responsibility to Recontact Research Participants after Reinterpretation of Genetic and Genomic Research Results
AU - Bombard, Yvonne
AU - Brothers, Kyle B.
AU - Fitzgerald-Butt, Sara
AU - Garrison, Nanibaa’ A.
AU - Jamal, Leila
AU - James, Cynthia A.
AU - Jarvik, Gail P.
AU - McCormick, Jennifer B.
AU - Nelson, Tanya N.
AU - Ormond, Kelly E.
AU - Rehm, Heidi L.
AU - Richer, Julie
AU - Souzeau, Emmanuelle
AU - Vassy, Jason L.
AU - Wagner, Jennifer K.
AU - Levy, Howard P.
N1 - Funding Information:
The workgroup (see members below) would like to thank Jillian Galloway, Chloe Mighton, and Nikki Meadows for assistance with the development of this statement. Y.B. was supported in part by an early career investigator award from the Canadian Institutes of Health Research . N.A.G. was supported in part by National Institutes of Health grant K01 HG008818 . The effort of G.P.J. was supported in part by National Institutes of Health grants U01HG008657 and U01HG007307 . H.L.R. was supported in part by National Institutes of Health grants U41HG006834 and U01HG008676 . J.B.M.’s effort was supported in part by UL1TR002014 through the National Center for Advancing Translational Sciences , National Institutes of Health . J.L.V. was supported by grant IK2-CX001262 from the Veterans Affairs Office of Research and Development .
Funding Information:
The workgroup (see members below) would like to thank Jillian Galloway, Chloe Mighton, and Nikki Meadows for assistance with the development of this statement. Y.B. was supported in part by an early career investigator award from the Canadian Institutes of Health Research. N.A.G. was supported in part by National Institutes of Health grant K01 HG008818. The effort of G.P.J. was supported in part by National Institutes of Health grants U01HG008657 and U01HG007307. H.L.R. was supported in part by National Institutes of Health grants U41HG006834 and U01HG008676. J.B.M.?s effort was supported in part by UL1TR002014 through the National Center for Advancing Translational Sciences, National Institutes of Health. J.L.V. was supported by grant IK2-CX001262 from the Veterans Affairs Office of Research and Development.
Publisher Copyright:
© 2019 American Society of Human Genetics
PY - 2019/4/4
Y1 - 2019/4/4
N2 - The evidence base supporting genetic and genomic sequence-variant interpretations is continuously evolving. An inherent consequence is that a variant's clinical significance might be reinterpreted over time as new evidence emerges regarding its pathogenicity or lack thereof. This raises ethical, legal, and financial issues as to whether there is a responsibility to recontact research participants to provide updates on reinterpretations of variants after the initial analysis. There has been discussion concerning the extent of this obligation in the context of both research and clinical care. Although clinical recommendations have begun to emerge, guidance is lacking on the responsibilities of researchers to inform participants of reinterpreted results. To respond, an American Society of Human Genetics (ASHG) workgroup developed this position statement, which was approved by the ASHG Board in November 2018. The workgroup included representatives from the National Society of Genetic Counselors, the Canadian College of Medical Genetics, and the Canadian Association of Genetic Counsellors. The final statement includes twelve position statements that were endorsed or supported by the following organizations: Genetic Alliance, European Society of Human Genetics, Canadian Association of Genetic Counsellors, American Association of Anthropological Genetics, Executive Committee of the American Association of Physical Anthropologists, Canadian College of Medical Genetics, Human Genetics Society of Australasia, and National Society of Genetic Counselors.
AB - The evidence base supporting genetic and genomic sequence-variant interpretations is continuously evolving. An inherent consequence is that a variant's clinical significance might be reinterpreted over time as new evidence emerges regarding its pathogenicity or lack thereof. This raises ethical, legal, and financial issues as to whether there is a responsibility to recontact research participants to provide updates on reinterpretations of variants after the initial analysis. There has been discussion concerning the extent of this obligation in the context of both research and clinical care. Although clinical recommendations have begun to emerge, guidance is lacking on the responsibilities of researchers to inform participants of reinterpreted results. To respond, an American Society of Human Genetics (ASHG) workgroup developed this position statement, which was approved by the ASHG Board in November 2018. The workgroup included representatives from the National Society of Genetic Counselors, the Canadian College of Medical Genetics, and the Canadian Association of Genetic Counsellors. The final statement includes twelve position statements that were endorsed or supported by the following organizations: Genetic Alliance, European Society of Human Genetics, Canadian Association of Genetic Counsellors, American Association of Anthropological Genetics, Executive Committee of the American Association of Physical Anthropologists, Canadian College of Medical Genetics, Human Genetics Society of Australasia, and National Society of Genetic Counselors.
UR - http://www.scopus.com/inward/record.url?scp=85063538793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063538793&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2019.02.025
DO - 10.1016/j.ajhg.2019.02.025
M3 - Review article
C2 - 30951675
AN - SCOPUS:85063538793
VL - 104
SP - 578
EP - 595
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
SN - 0002-9297
IS - 4
ER -